SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-137444
Filing Date
2021-11-12
Accepted
2021-11-12 07:06:11
Documents
13
Period of Report
2021-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2132707d1_8k.htm   iXBRL 8-K 26538
2 EXHIBIT 99.1 tm2132707d1_ex99-1.htm EX-99.1 45983
  Complete submission text file 0001104659-21-137444.txt   255102

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20211112.xsd EX-101.SCH 3186
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20211112_lab.xml EX-101.LAB 34594
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20211112_pre.xml EX-101.PRE 22711
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2132707d1_8k_htm.xml XML 3735
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 211399497
SIC: 2834 Pharmaceutical Preparations